Aptose Bioscienc Stock Price, News & Analysis

Aptose Biosciences (OTC: APTOF), a clinical-stage precision oncology company, has announced the selection of Ernst & Young LLP (EY) as its new independent registered public accounting firm. The company will hold a reconvened shareholder meeting on August 22, 2025 at 10:00 a.m. ET to vote on EY's appointment and remuneration.

The meeting follows an adjournment from the Original Meeting held on May 27, 2025, which was paused to complete the search for a successor auditor. Shareholders of record as of April 22, 2025 who haven't previously voted can submit their proxies up to 48 hours before the reconvened meeting. Previously submitted proxies will remain valid for the reconvened meeting.

Aptose Biosciences (OTC: APTOF) has received a second advance of $2.0 million from Hanmi Pharmaceutical as part of an $8.5 million loan facility agreement. The company has now received a total of $4.5 million under this agreement announced on June 20, 2025.

The funding supports the development of tuspetinib (TUS), a daily oral treatment being tested in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia (AML) patients. The TUSCANY triplet Phase 1/2 study has shown promising early results, demonstrating safety and complete responses across diverse AML mutations, including TP53-mutated and wildtype AML populations.

Aptose Biosciences (OTC: APTOF), a clinical-stage precision oncology company, announced its upgrade to the OTCQB Market effective July 1, 2025. The company, which develops tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML), will maintain its listing on the Toronto Stock Exchange (TSX) under the symbol "APS".

The OTCQB Venture Market caters to early-stage and developing U.S. and international companies that meet current reporting requirements and undergo annual verification and management certification processes.

Aptose Biosciences (OTC: APTOF), a clinical-stage precision oncology company, has reached an agreement with Hanmi Pharmaceutical to defer interest payments on their 2024 loan facility. The company, which is developing tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML), will have two interest payments originally due on June 27, 2025, and June 30, 2025, deferred until December 31, 2025.

The deferred payments cover interest periods from December 21, 2024, to March 31, 2025, and from March 31, 2025, to June 30, 2025, respectively.

Aptose Biosciences has secured a new loan agreement with Hanmi Pharmaceutical for up to US$8.5 million to advance the development of tuspetinib (TUS) in triple drug therapy for acute myeloid leukemia (AML). The loan will support the ongoing TUSCANY Phase 1/2 clinical trial, which combines TUS with azacitidine and venetoclax for newly diagnosed AML patients ineligible for induction chemotherapy. Tuspetinib is an oral medication targeting multiple kinases including SYK, FLT3, KIT, JAK1/2, and RSK2. Early trial data from initial cohorts has shown promising results with complete responses and minimal residual disease negativity across patients with various mutations, while maintaining a favorable safety profile.

Aptose Biosciences, a clinical-stage precision oncology company, has secured a short-term cash advance from CEO Dr. William G. Rice to cover immediate obligations including payroll and continue development of tuspetinib, their oral kinase inhibitor. The advance is non-interest bearing, unsecured, and repayable without penalty. Despite this funding, Aptose warns it may face insolvency proceedings without additional funding in the coming days. The company also announced the resignation of board member Carol Ashe, effective June 16, 2025. The cash advance constitutes a related-party transaction under MI 61-101, though Aptose is exempt from formal valuation and minority shareholder approval requirements.

Aptose Biosciences presented promising clinical data from its TUSCANY Phase 1/2 trial evaluating tuspetinib (TUS) in combination with venetoclax and azacitidine for newly diagnosed AML patients. The study included 10 patients across three dosage cohorts (40mg, 80mg, 120mg). In the 40mg cohort, three patients achieved complete remissions with MRD-negativity. The 80mg cohort showed 100% composite complete remissions, while the 120mg cohort patients remain under treatment. Notably, the treatment demonstrated efficacy across diverse genetic populations, including challenging cases with TP53 mutations. The triplet therapy showed favorable safety with no dose-limiting toxicities, no treatment-related deaths, and all patients remaining alive. The trial continues at 10 leading U.S. clinical sites with expected enrollment of 18-24 patients by mid-late 2025.

Aptose Biosciences (OTC: APTOF), a clinical-stage precision oncology company, held its annual and special meeting on May 27, 2025, with 57.90% shareholder participation. All nominated directors were successfully re-elected with strong approval ratings above 97%. Shareholders approved key proposals including: an advisory resolution on executive compensation, amendments to the 2021 stock incentive plan, and a potential reverse stock split at a ratio between 1-for-2 to 1-for-20. The meeting was adjourned to allow time to find a successor auditor to KPMG LLP. The company is developing a tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients.

Aptose Biosciences has announced significant progress in its Phase 1/2 TUSCANY trial, evaluating tuspetinib (TUS) in combination with venetoclax and azacitidine for newly diagnosed AML patients. The Cohort Safety Review Committee (CSRC) has approved dose escalation from 80mg to 120mg of TUS following positive safety and efficacy data from initial cohorts. The trial has shown complete remissions (CRs) and minimal residual disease (MRD)-negativity across diverse mutations, with no significant safety concerns or dose-limiting toxicities. Notably, the treatment demonstrated effectiveness in difficult-to-treat populations, including patients with TP53 and RAS mutations. The TUSCANY trial, conducted at 10 leading U.S. clinical sites, aims to enroll 18-24 patients by mid-late 2025. Updated data will be presented at the European Hematology Association Congress in June 2025.